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Mismatch recognition in human cells is mediated primarily
by a heterodimer of hMSH2 and hMSH6. Cells mutated
in both alleles of the hMSH6 gene are deficient in the
correction of base/base mispairs and insertion/deletion
loops of one nucleotide and thus exhibit a strong mutator
phenotype, evidenced by elevated mutation rates and micro-
satellite instability, as well as by tolerance to methylating
agents. The decrease in replication fidelity associated with
a loss of mismatch correction implies that with each
division, these cells are likely to acquire new mutations
throughout their genomes. Should such secondary
mutations occur in genes linked to replication fidelity or
involved in the maintenance of genomic stability, they
might contribute to the observed mutator phenotype. The
human colon tumour line HCT15 represents one such case.
Although it carries inactivating mutations in both hMSH6
alleles, it has also been shown to contain a missense
mutation in the coding sequence of the proofreading domain
of the polymerase-d gene. In an attempt to find out whether
the phenotype of HCT15 cells was indeed brought about
solely by the lack of hMSH6, we stably transfected them
with a vector carrying the wild-type hMSH6 cDNA. Our
results show that although the levels of transgenic hMSH6
were low, expression of the wild-type protein resulted in a
substantial restoration of mismatch binding, mismatch
repair capacity and the stability of mononucleotide repeats,
as well as in the reduction of mutation rates. Although
methylation tolerance of the hMSH6-expressing cells was




Mutations in genes encoding mismatch repair proteins have
been found in both sporadic and hereditary colon cancers (1–
4). Post-replicative mismatch correction increases the fidelity
Abbreviations: BrdU, 5-bromo-29-deoxyuridine; DMEM, Dulbecco’s modi-
fied Eagle’s medium; DMSO, dimethylsulphoxide; DTT, dithiothreitol;
HNPCC, hereditary non-polyposis colon cancer; HU, hydroxyurea; IDL,
insertion/deletion loop; MGMT, O6-methylguanine methyltransferase; MNNG,
N-methyl-N9-nitro-N-nitrosoguanidine; MNU, N-methyl-N-nitrosourea; PBS,
phosphate-buffered saline; PMSF, phenylmethylsulphonyl fluoride; pol,
polymerase; RER, replication error in repeats; 6-TG, 6-thioguanine.
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of DNA replication by up to three orders of magnitude in all
organisms studied to date (5). Cells deficient in mismatch
repair display elevated spontaneous mutation frequencies,
instability of repeated sequence motifs (e.g. microsatellites),
increased gene conversion and recombination levels (4,6,7)
and tolerance to certain types of DNA-modifying drugs (8).
Our understanding of this repair pathway in human cells has
been greatly facilitated by the fact that the process is highly
conserved throughout evolution. Thus, genetic and biochemical
studies of mismatch repair in lower organisms, in particular
Escherichia coli and Saccharomyces cerevisiae, have been
extremely informative. Moreover, the different phenotypes of
human tumour-derived mismatch repair-deficient cells helped
to elucidate the roles of the individual mismatch repair proteins
in the correction process. Biochemical studies carried out with
extracts of these cells were instrumental in the discovery that,
while in E.coli the initial steps of mismatch correction are
mediated by the homodimeric MutS and MutL proteins,
recognition of base/base mispairs and small insertion/deletion
loops (IDLs) in human extracts is mediated primarily by
hMutSα, an abundant heterodimer of two MutS homologues,
hMSH2 and hMSH6 (the latter is also known as GTBP
or p160) (9–11). The resulting protein–DNA complex is
subsequently bound by a second heterodimer, hMutLα, com-
posed of hMLH1 and hPMS2 (12). The system also appears
to have some built-in redundancy, as a second heterodimer,
hMutSβ, composed of hMSH2 and hMSH3, participates in the
correction of IDLs, but not base/base mispairs (13–16).
There is little doubt that inheritance of mutations in mismatch
repair genes, especially in hMLH1 and hMSH2, predisposes
to cancer of the colon, endometrium and ovary, as witnessed
by the high frequency of these types of tumours in hereditary
non-polyposis colon cancer (HNPCC) families (2). Indeed, the
discovery that tumour tissue from HNPCC patients exhibited
microsatellite instability, a phenotype referred to as replication
error in repeats (RER1) (17), instigated the search for defects
in DNA replication or post-replicative repair. There is also
ample evidence that the RER1 phenotype, elevated mutation
frequency, mismatch repair deficiency and tolerance to methyl-
ating agents are linked with mutations in mismatch repair
genes (3,4,18). However, unambiguous evidence that these
mutations are entirely responsible for the observed phenotype
is still lacking. This is due to the fact that mismatch repair-
deficient cells have a propensity to acquire new mutations
during each replication cycle. The possibility that such
mutations could have arisen in other genes involved in the
maintenance of genomic integrity could therefore not be
excluded. A case in point is the human colon tumour line
HCT15. These cells carry a mutated hMSH6 gene, with one
allele having been inactivated by a single nucleotide deletion
mutation in codon 222 which results in a change from leucine
to a termination codon and the other allele having a complex
deletion/substitution mutation (GATAGA→T) at codon 1103,
which causes protein synthesis to terminate three amino acid
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residues downstream (19). HCT15 cells are, correspondingly,
defective in the correction of base/base mismatches and small
IDLs, as measured by an in vitro assay (9), and have a strong
mutator phenotype (20,21). They are also tolerant to high
concentrations of methylating agents (22). However, an earlier
study also identified a mutation in the polymerase (pol)-δ
gene, where a G→A transition mutation alters a conserved
amino acid residue that is located in the 39→59 proofreading
exonuclease domain of the protein (23). As mutations in the
proofreading exonuclease subunits of other polymerases are
known to possess extremely strong mutator phenotypes (24),
there exists the possibility that the pol-δ mutation contributes
to the phenotype of HCT15 cells. One way to answer this
question is to express the wild-type hMSH6 protein in these
cells and to see whether the mutator phenotype of the trans-
fected cells has been corrected. We now report that expression
of wild-type hMSH6 in HCT15 cells resulted in a substantial
correction of the defects in mismatch binding and base/
base mispair correction and restored stability to microsatellite
sequences. Although expressed only at low levels, wild-type
hMSH6 also brought about a modest reduction in mutation
rate at the HPRT locus. The sensitivity of the hMSH6-
expressing HCT15 cells to methylating agents remained largely
unaltered, but the G2 cell cycle checkpoint, which is generally
absent from mismatch repair-deficient cells following treatment
with methylating agents (25), appears to have been restored.
Materials and methods
The reagents used in these experiments were obtained from the following
sources: pCDNA-3 from Invitrogen (San Diego, CA); G418 (Geneticin) from
Gibco BRL Life Technologies (Gaithersburg, MD). N-methyl-N-nitrosourea
(MNU; Sigma, St Louis, MO) was dissolved in dimethylsulphoxide (DMSO)
and diluted in phosphate-buffered saline (PBS)/20 mM HEPES, pH 7.4, to
the required concentration immediately before use. A stock solution of
O6-benzylguanine (a kind gift of J.Thomale, University of Essen, Essen,
Germany) was prepared in DMSO and stored at –20°C. The Megaprime DNA
labelling system was from Amersham International (Little Chalfont, UK);
Dulbecco’s modified Eagle’s medium (DMEM) was from Gibco; the HCT15
cell line was kindly provided by Dr Thomas Kunkel (NIEHS, NC). Standard
laboratory procedures were carried out according to Sambrook et al. (26).
Construction of the hMSH6 cDNA expression vector
The full-length hMSH6 cDNA (10,27) was excised from plasmid pBluescript
hMSH6 (10) with BamHI and XhoI. The 4283 bp fragment was ligated
between the BamHI and XhoI sites of pCDNA-3. The resulting plasmid,
pCDNA/hMSH6, and the control, insert-less pCDNA-3 vector were purified
by isopycnic centrifugation on a CsCl gradient and transfected into HCT15
cells. The insert in the H-5 clone was then sequenced to ensure that no
mutations were present in the hMSH6 coding region.
Transfection of HCT15 cells and selection of stable clones
The HCT15 cells were grown in DMEM supplemented with 10% fetal bovine
serum (Gibco), in a humidified 5% CO2 atmosphere at 37°C. The DNA
transfection of HCT15 cells was performed by the calcium phosphate
precipitation technique. Briefly, logarithmically growing cells were sub-
cultured at a density of 13106 cells/10 cm dish and 24 h later 20 µg plasmid
DNA/calcium phosphate precipitate were left on the cells overnight. The cells
were washed and incubated for 2 days in fresh culture medium, whereupon
selection was initiated by the addition of G418 to the growth medium at
900 µg/ml. After 3 weeks, the resistant colonies were collected in cloning
rings and propagated into mass cultures. Three weeks later, the colonies were
analysed for hMSH6 expression. The clones stably expressing hMSH6 were
maintained in a medium containing 900 µg/ml G418. One clone, named
H-5, expressing the highest level of hMSH6 (see below), was selected for
further study. A second clone, named H-c, stably transfected with the empty
expression vector, was used as a control.
Preparation of nuclear extracts
Nuclear extracts were prepared according to the method of Dignam et al.
(28). The harvested cells were washed twice with PBS, collected and dissolved
in 1 vol ice-cold buffer A [10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM
374
MgCl2, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulphonyl fluoride
(PMSF)]. After 15 min incubation on ice, the cells were homogenized with
15 strokes in a glass micro-Dounce homogenizer pre-rinsed with buffer A.
The homogenate was centrifuged in an Eppendorf microfuge for 20 s at
12 000 r.p.m. The nuclear pellets were resuspended in two-thirds vol ice-cold
buffer C (20 mM HEPES, pH 7.9, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 20% glycerol, 1 mM DTT, 1 mM PMSF) and incubated for 30 min
at 4°C on a rotating wheel. The samples were then centrifuged for 5 min at
12 000 r.p.m. and the supernatant was collected, snap frozen in small aliquots
in liquid nitrogen and stored at –80°C.
Band shift assays
The band shift assays were carried out as described previously (29). Briefly,
32P-labelled 34mer oligonucleotide duplexes, either perfectly matched (G/C)
or containing a single G/T mismatch (G/T), were incubated with 15 µg nuclear
extract in the presence of 25 mM HEPES–KOH, pH 8.0, 0.5 mM EDTA,
10% (v/v) glycerol, 0.5 mM DTT and 1 µg poly(dI·dC) competitor DNA
(Boehringer Mannheim, Mannheim, Germany) in a total volume of 20 µl.
The mixture was allowed to stand at room temperature for 20 min. Five
microliters of the mixture were loaded onto a 6% non-denaturing polyacryl-
amide gel run in 13 TAE buffer. Electrophoresis was carried out at 150 V
until the bromophenol blue dye, loaded in an adjacent well, migrated ~7 cm.
The dried gels were autoradiographed at –80°C.
Immunoblotting (western) analysis
Aliquots of 25–100 µg nuclear extract were loaded on 7.5% SDS–poly-
acrylamide gels. After electrophoresis, the proteins were transferred to a
nitrocellulose membrane (Schleicher & Schuell) by electroblotting at 30 V
overnight at 4°C in 25 mM Tris, 192 mM glycine and 20% methanol. The
membrane was blocked with 5% low fat milk in TBST (100 mM Tris–HCl,
pH 8, 150 mM NaCl, 0.05% Tween 20) for 1 h at room temperature. The
membrane was then incubated for 1 h at room temperature with mouse
monoclonal anti-hMSH6 (15) and anti-hMSH2 (AB-2; Calbiochem) antibodies
at a final concentration of 0.8 and 0.2 µg/ml, respectively. After three washes
with TBST, the membrane was incubated with alkaline phosphatase-conjugated
anti-mouse IgG (1:4000; Sigma) for 1 h at room temperature and developed
according to the manufacturer’s (Sigma) instructions.
Northern blot analysis
Total RNA was extracted from logarithmically growing HeLa, H-c and H-5
cells with TRIzol reagent (Gibco BRL). Aliquots of 30 µg were then suspended
in formamide loading buffer and electrophoresed on a 1% formaldehyde–
agarose gel. The positions of the 28S and 18S rRNAs were determined by
inspection on a UV transilluminator and the gel was then blotted for 16 h in
203 SSC on a Genescreen nylon membrane (DuPont/NEN, Keene, NH). The
filter was rinsed in 23 SSC, baked under vacuum for 1 h at 80°C and
crosslinked for 30 s in a Stratalinker (Stratagene, La Jolla, CA). Prehybridiza-
tion was performed in 53 SSPE, 50% formamide, 53 Denhardt’s solution,
1% SDS, 10% dextran sulphate and 100 mg/ml denatured salmon sperm DNA
for 2 h at 42°C. Hybridization was carried out in the same buffer containing
13106 c.p.m./ml 32P-labelled random primed 2 kb gel-purified hMSH6
fragment for 16 h at 42°C. The membrane was washed once at room
temperature in 23 SSPE (10 min), once at 65°C in 23 SSPE, 2% SDS
(10 min) and the filter was then air dried and autoradiographed.
RT–PCR analysis of hMSH6 expression in HeLa, H-c and H-5 cells
hMSH6 cDNA was synthesized by reverse transcription, starting from 4 µg
total RNA. Following denaturation by heating for 5 min at 75°C, a mixture
containing 100 pmol oligo d(T)12–18 primer (Pharmacia Biotech, Uppsala,
Sweden) and 1000 U Moloney murine leukaemia virus reverse transcriptase
(M-MLV 200 U/µl; Promega, Madison, WI) in 20 µl 10 mM DTT, 50 mM
Tris–HCl, pH 8.3, 75 mM KCl, 3 mM MgCl2 and 0.2 mM each deoxynucleoside
triphosphate (Pharmacia Biotech) was added and the reaction was incubated
for 1 h at 37°C. The enzyme was inactivated by heating for 5 min at 95°C.
The PCR primers pT7 (TAATACGACTCACTATAGGG), C15r (AACTGTA-
CATGAACACGGA) and Nick5 (CGGGATCCGATGTCGCGACAGAGC-
ACC; Figure 1a) were then used to amplify the hMSH6 transcripts. PCR was
performed using 35 cycles of 95°C for 1 min, 50°C for 45 s and 72°C for
90 s in 13 buffer (Stratagene) with 100 ng HeLa cDNA or with 50 ng H-c
or H-5 cDNA, 5% DMSO, 0.2 mM each deoxynucleoside triphosphate,
1 mM each primer and 2.5 U Taq polymerase (Taq-plus Precision PCR
System; Stratagene). The products were separated by electrophoresis in an
agarose gel containing ethidium bromide and visualized on a UV trans-
illuminator (Figure 1c).
Mutation rate analysis
The H-c and H-5 cells were plated at low density (100 cells/dish) to ensure
the absence of pre-existing mutants. The cultures were grown to between
53104 and 1.53106 cells/dish. All cells in each replicate were plated into
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Fig. 1. Northern blot and RT–PCR analysis of hMSH6 expression in H-5 cells. (a) Schematic representation of the retroviral expression vector. P CMV,
enhancer/promoter cassette of cytomegalovirus; BGHpA, bovine growth hormone polyadenylation signal sequence. Arrows indicate the position and
orientation of primers used in the RT–PCR experiments. The dashed arrow indicates the transcription start site. (b) Hybridization of total RNA extracted from
HeLa, H-c and H-5 cells with either a radiolabelled hMSH6 probe (top) or with a reference β-actin probe (bottom). (c) RT–PCR analysis of hMSH6
expression. Amplification of hMSH6 cDNA reverse transcribed from total mRNA isolated from HeLa, H-c and H-5 cells. PCR reactions with the primer pair
Nick5/C15r amplified both endogenous and transgenic hMSH6 cDNA. In contrast, only transgenic cDNA was amplified with the primer pair pT7/C15r
[see (a)]. Plasmids pCDNA and pCDNA/hMSH6 were used as controls. In the two right-most lanes are the negative controls, where the amplification
reactions were carried out with both primer pairs in the absence of DNA.
selective medium containing 6-thioguanine (6-TG; Sigma) at a density ø53105
cells/10 cm dish. Colonies were grown for 2 weeks before fixing with methanol
and staining with 10% Giemsa in aqueous solution. Only colonies with .50
cells were counted. Mutation rates were calculated by the method of the
mean (20).
DNA sequence analysis of HPRT mutations
H-c and H-5 cells were plated at a density of 100 cells/dish and grown to a
final number of 53105 cells. The replica cultures were trypsinized and plated
in 6-TG at a density of 1253103 cells/10 cm dish. After 2 weeks, the colonies
were picked with cloning cylinders and grown to confluence in 24-well tissue
culture plates. RNA was isolated from the HPRT– mutants with TRIzol
reagent. The mutant RNAs were reverse transcribed as described above using
a HPRT primer complementary to the 39-end of the non-coding region
(GTTTCCAAACTCAACTTGAACTCTC). The cDNA products were ampli-
fied using a second primer (CCGGCTTCCTCCTCCTGAGC) complementary
to the 59-end of the gene. The PCR products were purified and sequenced
with nested primers according to the ABI PRISM dRhodamine terminator
cycle sequencing reaction kit (Perkin Elmer/Applied Biosystems, Wilton, CT).
In mutants displaying loss of exons from the cDNAs, genomic DNA was
extracted by standard methods and the exon–intron boundaries were PCR
amplified with specific primers. The sequencing reactions were performed
with nested primers.
Mismatch repair assays
The efficiency of cytoplasmic extracts of the stably transfected cells in
repairing DNA mismatches was tested as described previously (15). Briefly,
cytoplasmic extracts were prepared from 53108 HeLa, parental HCT15, H-c
and H-5 cells harvested in the logarithmic growth phase. Following resuspen-
sion in an appropriate volume of ice-cold hypotonic buffer to yield a cell
density of 13108 cells/ml, the cells were allowed to swell for 10 min in a
glass Dounce homogenizer (Kontes, Vineland, NJ) on ice and then lysed
mechanically with four or more strokes with a tight (type B) pestle. When
.80% of cells were lysed, the nuclei were pelleted and the supernatant was
centrifuged at 12 000 g for 10 min at 4°C, frozen in liquid nitrogen in aliquots
and stored at –80°C. The protein concentration was determined by the Bradford
method (30). M13mp2 DNA heteroduplexes containing a G/G, G/T or T/G
base mispairs in the coding sequence of the lacZ α-complementation gene
were obtained by hybridizing single-stranded viral (1) DNA with the (–)
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strand of linearized RF DNA. One femtomole of the respective heteroduplex
was used in a repair reaction (25 µl) with 30 mM HEPES, pH 7.8, 7 mM
MgCl2, 4 mM ATP, 200 µM each CTP, GTP and UTP, 100 µM each dATP,
dGTP, dTTP and dCTP, 40 mM creatine phosphate, 100 fmol creatine
phosphokinase, 15 mM sodium phosphate, pH 7.5, and 50 µg protein extract.
The incubation was carried out at 37°C for 20 min. The repair was directed
to the (–) strand of M13mp2 by the presence of a nick. The DNA heteroduplex
was then purified and introduced by electroporation into Escherichia coli
NR9162 (mutS strain), plated on minimal medium in a soft agar layer
containing 0.5 ml of a log phase culture of CSH50 (the α-complementation
strain), 0.5 µg isopropyl-β-D-thiogalactopyranoside and 2 µg 5-bromo-4-
chloro-3-indoyl-β-D-galactopyranoside. Following incubation for 16 h at 37°C,
the plaques were assigned to one of the following phenotypes: blue, colourless
or mixed. If no repair occurred, mixed plaques were observed containing both
blue and colourless progeny. Repair of the substrate reduced the percentage
of mixed plaques and increased the percentage of pure colour plaques. As the
nick directs repair to the (–) strand, the (1) phenotype increases and the (–)
phenotype decreases.
Microsatellite analysis
A 121 bp region encompassing 26 deoxyadenosines localized in an intron
of hMSH2 (BAT26) was amplified by PCR using 4,7,29,7’-tetrachloro-6-
carboxyfluorescein-labelled forward primer 59-TGACTACTTTTGACTT-
CAGCC-39 and reverse primer 59-AACCATTCAACATTTTTAACCC-39
(300 nM each). The amplification was carried out in 25 µl total volume with
GenAmp 13 PCR buffer (Perkin Elmer), 1.25 U AmpliTaq Gold DNA
polymerase (Perkin Elmer), 1.5 mM MgCl2, 100 µM deoxynucleotide triphos-
phates and 5 ng genomic DNA extracted from each single cell clone. After 1
cycle of 94°C for 9 min to activate AmpliTaq DNA polymerase, 30 cycles of
94°C for 45 s, 51°C for 1 min and 70°C for 30 s and a final elongation step
at 70°C for 7 min were performed. Mock reactions without DNA were
performed with every twentieth sample and were always negative. After
dilution, the PCR products were denatured with formamide at 92°C for 2 min
and electrophoresed through a polymer capillary in an ABI PRISM 310
Genetic Analyzer (Perkin Elmer). The sizing and quantitation of the DNA
fragments was performed with the GenScan Analysis software (Perkin Elmer).
Methylation tolerance studies
This experiment was carried out as described previously (31). To measure
cell survival, 100 cells were treated 18 h after seeding in 6 cm dishes for
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30 min at 37°C with various concentrations of MNU in PBS/20 mM HEPES,
pH 7.4. Cells were then washed, fed with complete medium and, 1–2 weeks
later, the surviving colonies were fixed with methanol, stained with Giemsa and
counted. In the experiments performed in the presence of O6-benzylguanine, the
drug was added to the medium at a final concentration of 25 µM 2 h prior to
the MNU treatment and kept in the medium for an additional 72 h.
Cell cycle analysis
Cell synchronization in early S phase was accomplished by treatment with
hydroxyurea (HU; Sigma). Confluent cells arrested in the resting phase were
replated in fresh complete medium along with 2 mM HU to allow G1 traverse.
Fourteen hours later, by which time all cells had accumulated in early S phase,
the HU was removed by two washes with prewarmed serum-free medium. The
cells were then treated with 0 or 5 µM N-methyl-N9-nitro-N-nitrosoguanidine
(MNNG; Sigma) in serum-free medium for 45 min at 37°C and 5% CO2.
After treatment, they were washed once with 10% serum-containing medium
and returned to drug-free 10% serum-containing medium for 2, 4.5, 7, 12, 15
and 19 h. At each time point, the cells were incubated with 10 µM 5-bromo-
29-deoxyuridine (BrdU; Sigma) for 30 min before harvesting. They were then
washed with PBS, fixed in 70% ethanol and stored at 4°C. Nuclear preparation
and dual labelling of DNA by propidium iodide (Sigma) and anti-BrdU–
fluorescein conjugate (Boehringer Mannheim, Basel, Switzerland) were per-
formed as described (25). Cell cycle analysis was performed using a Becton
Dickinson (Lincoln Park, NJ) FACscan flow cytometer and Cell Quest
software. The data analysis is based on two independent experiments.
Results
Stable transfection of HCT15 cells with a retroviral vector
carrying the hMSH6 cDNA results in the expression of
hMSH6 mRNA
The expression vehicle pCDNA-3 is an integrating retroviral
vector containing a selectable marker gene that confers resist-
ance to G418. The hMSH6 cDNA was cloned between the
cytomegalovirus enhancer/promoter cassette and a polyadenyl-
ation signal sequence of the human growth hormone gene.
The correct orientation of the insert was ensured by directional
cloning between BamHI and XhoI sites of the vector (Figure 1a;
see also Materials and methods).
The hMSH6 expression vector pCDNA/hMSH6 was trans-
fected into logarithmically growing HCT15 cells by calcium
phosphate precipitation. Following long-term selection for
G418 resistance, a total of 10 clones were obtained, which
were selected and grown into mass cultures under constant
selective pressure. These clones were tested for the presence
of integrated hMSH6 cDNA by Southern blotting, as well as
for expression of the protein by band shift and immunoblotting
assays. Of these 10 clones, two, H-2 and H-5, contained
detectable amounts of hMSH6 cDNA. We selected clone H-5
for further analysis. Southern blot experiments indicated that
H-5 carries about three copies of the integrated vector DNA
(data not shown).
Because the H-5 clone was resistant to G418, the selectable
marker gene was clearly expressed from the transfected vector.
We therefore decided to test whether this clone also expressed
hMSH6 mRNA. To this end, total RNA isolated from HeLa,
H-c (control, HCT15 cells stably transfected with the empty
pCDNA-3 vector) and H-5 cells was size fractionated on an
agarose gel, transferred to a nitrocellulose membrane and
hybridized with a radiolabelled hMSH6 probe as described in
Materials and methods. The relative quantities of the specific
signals were normalized with respect to β-actin. As shown in
Figure 1b, the amount of hMSH6 mRNA in the H-5 clone
corresponded to ~50% of that seen in HeLa cells. In contrast,
the H-c clone expressed only low amounts of hMSH6 mRNA.
It is possible that the hMSH6 promoter is epigenetically
inactivated in the H-c cells. However, we consider it more
likely that the mRNA is selectively degraded due to the
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Fig. 2. (a) Immunoblot analysis of HeLa, H-c and H-5 extracts. Monoclonal
antisera to hMSH6 and hMSH2 recognized bands of 160 and 100 kDa,
respectively. Aliquots of 100 µg H-c and H-5 extracts were loaded. Aliquots
of 25–100 µg HeLa extract were loaded in order to aid in quantitation of
the hMSH6 signal observed in the transfected cell extracts. M, molecular
size markers (Bio-Rad, Hercules, CA). (b) Mismatch binding activity in
extracts of H-c and H-5 cells. The extracts were incubated with
radioactively labelled oligonucleotide duplexes either complementary (G/C)
or containing a single G/T mispair (G/T, see Materials and methods). The
G/T-specific complex was absent in H-c extracts that lack hMSH6, but was
restored upon expression of hMSH6 in H-5 cells. The extract of mismatch
repair-proficient HeLa cells was used as a control.
presence of the premature termination codons (32). This result
indicates that the 4.2 kb signal seen in the stably transfected
clone H-5 is due almost entirely to the transcript originating
from the transgene. We could substantiate this prediction
further by the RT–PCR experiments shown in Figure 1c. Using
two primer pairs, one specific for the RNA expressed from
the transgene and one generic (Figure 1a, primers pT7/C15r
and Nick5/C15r, respectively), we could show that while a
fragment of 420 bp was obtained following RT–PCR of all
three lines (Figure 1a, lanes Nick5-C15r), a transgene-specific
signal was visible solely in the H-5 clone (Figure 1a, lanes
T7-C15r). This result conclusively proved that the hMSH6
transcript originated from the integrated expression vector.
Expression of hMSH6 in H-5 cells restores mismatch binding
activity
Western blotting experiments confirmed that the hMSH6 tran-
script was also translated, as the extracts of the H-5 clone
contained hMSH6 (Figure 2a). In extracts of mismatch repair-
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Fig. 3. Mismatch repair assays. (a) Correction efficiency of the G/T, T/G
and G/G M13mp2 heteroduplex substrates, carrying a strand discrimination
signal either 59 or 39 from the mispair. (b) Complementation of H-c and
H-5 extracts with purified recombinant hMutSα.
proficient cells, such as HeLa shown in this example, the
hMSH2 and hMSH6 proteins are present in a 1:1 ratio, while
the extracts of H-c cells contained only hMSH2 in detectable
amounts (10). Quantification of the immunoblot revealed that
the amount of hMSH6 in H-5 extracts was only ~20% of the
hMSH2 level. These extracts therefore contain about five times
less hMutSα than HeLa cells.
The band shift assay shown in Figure 2b revealed that
nuclear extracts of H-5 cells contained a mismatch-specific
DNA binding activity, with a mobility similar to that present
in extracts of HeLa cells, while no similar protein–DNA
complex was present in the extracts of the control clone,
H-c. We therefore assigned the mismatch-specific activity to
hMutSα.
H-5 extracts are proficient in mismatch repair
The extracts of H-5 and H-c cells were tested for mismatch
correction efficiency in vitro, using circular M13 heteroduplex
substrates carrying either the G/T, T/G or G/G mispairs and
strand directional signals (nicks) either 59 or 39 from the
mispairs (see Materials and methods). As shown in Figure 3a,
mismatch repair was restored in the H-5 extracts, with all
substrates having been corrected to a level at least 5-fold
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Table I. Microsatellite instability of the BAT26 locus of H-c and H-5 cells
Cell line Stable clones Unstable clones
H-c 67 23
H-5 84 5
Table II. Mutation rates at the HPRT locus of H-c and H-5 cells
Cell line Initial Final No. of Mutant Mutation
cell no. cell no. replica colonies rate
cultures (mean3no.)
H-c 100 1.0513106 23 158 6 0.6 2.5310–5
H-5 100 1.1513106 23 55 6 11 0.8310–5
H-c:H-5 ratio 3.1
above background. This repair capacity was relatively low,
however, especially when compared with HeLa extracts, which
typically repair .90% of the substrate in this assay (data not
shown). We therefore decided to test whether this reduced
repair capacity was due solely to the low levels of hMSH6
expression or whether the extracts were of poor quality. To
this end, we added recombinant hMutSα to the extracts and
determined if this improved the repair efficiency. As shown in
Figure 3b, complementation of repair-deficient extracts of
HCT15 and H-c cells resulted in the correction of nearly 90%
of the G/G substrate. A substantial improvement was also
observed in the H-5 extracts, which indicated that the repair
capacity of these extracts was limited by the quantity of
hMutSα. Taken together, the results of the western blotting,
band shift and in vitro mismatch repair experiments all showed
that the amount of hMutSα expressed in H-5 cells is limiting.
Microsatellite instability is alleviated in the H-5 clone
Despite the low protein levels, we decided to test whether
expression of hMSH6 in the H-5 clone affected the micro-
satellite instability of these cells. We decided to use the BAT26
marker, which targets a repeat of 26 adenines and has been
shown to be exquisitely sensitive to mutations in hMSH6 (19).
Analysis of 90 H-c and 89 H-5 clones showed that expression
of hMSH6 in HCT15 cells was sufficient to greatly alleviate
microsatellite instability (Table I). Thus, while 23 of the
examined H-c clones displayed instability at this locus, only
five H-5 clones did. This difference is highly statistically
significant (P 5 0.0002). All mutations detected were deletions
of a further nucleotide in the already shortened BAT26 poly(A)
microsatellite of the HCT15 cells.
Mutation rate is decreased in H-5 cells
HCT15 cells display a strong mutator phenotype. Mutation
rate measured at the HPRT locus is elevated ~200- to
600-fold as compared with mismatch repair-proficient cells
(21,33). We therefore determined the mutation rate at this
locus for the H-c and H-5 clones. The data shown in Table II
indicate that expression of hMSH6 in HCT15 cells did indeed
reduce the mutation rate, albeit only ~3-fold.
Although this reduction might appear of little significance,
sequencing of the mutated HPRT cDNA revealed that the
mutation spectra of the control and the H-5 cells were different
(Table III). Thus, while transition, transversion and frameshift
mutations represented 33, 45 and 12% of changes observed in
the mutated HPRT gene of the control cells, the H-5 line
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Table III. Spontaneous mutation spectra of the HPRT locus of H-c and H-5
cells
H-c H-5
Mutations characterized 24 26
Transitions 8 (33%) 4 (15%)
A:T→G:C 4 2
G:C→A:T 4 2
Transversions 11 (45%) 17 (65%)
G:C→T:A 8 14
G:C→C:G 0 1
T: A→A:T 3 0
A:T→C:G 0 2
Frameshifts 3 (12%) 1 (4%)
Deletions 0 4 (15%)
Undefined mutations 2 (8%) 0
Table IV. Progression of the untreated or MNNG-treated H-c and H-5 cells
through the cell cycle after release from an HU block
Cell cycle Time post-release H-c H-c/MNNG H-5 H-5/MNNG
phase (h) (%) (%) (%) (%)
G1 2 1.7 12.5 6.1 16.7
4.5 4.1 8.7 1.8 7.7
7 6.1 10.1 1.9 3.7
9 10.4 4.6 8.9 5.8
12 12.1 13.2 12.9 4.5
15 41.1 36.1 36.1 9.7
19 22.9 24.6 12.8 22.1
S 2 97.8 86.8 93.3 78.5
4.5 93.9 88.2 97.4 87.3
7 64.4 67.9 72.2 91.3
9 34.5 42.3 37.5 79.6
12 12.1 30.1 9.1 76.9
15 53.1 43.3 54.9 55.1
19 71.4 72.5 80.4 46.6
G2/M 2 0.5 0.7 0.5 4.8
4.5 1.9 3.1 0.7 4.9
7 29.6 22.1 25.9 4.9
9 55.1 53.1 53.6 14.6
12 75.8 56.7 78.1 18.6
15 5.9 20.5 8.9 35.2
19 5.7 2.8 6.7 31.4
displayed primarily transversions and deletions of multiple
bases. Transitions and frameshifts, which arise from uncorrec-
ted purine/pyrimidine mispairs and insertion/deletion loops,
respectively, were less frequent. It is interesting to note in
this respect that the latter premutagenic lesions are the best
substrates for hMutSα in in vitro mismatch binding assays
(34), as well as being the most efficiently corrected mispair
types in vivo (35). It is therefore likely that although the level
of hMutSα in the H-5 cells is low, it is nonetheless sufficient
to mediate the correction of a significant proportion of those
substrates which it binds with the highest affinity (see also
below).
H-5 cells are not significantly sensitized to killing by
methylating agents
Treatment of cells with simple methylating agents introduces
numerous modifications into DNA. However, it could be shown
that the lesion primarily responsible for the cytotoxicity of these
substances is O6-methylguanine. Resistance to methylating
agents is commonly associated with overexpression of O6-
methylguanine methyltransferase (MGMT), which reverses the
damage by removing methyl groups from modified guanines
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Fig. 4. Sensitivity of the H-c and H-5 cells to methylating agents. The
cells were treated with MNU in the absence (a) or presence (b) of
O6-benzylguanine (see Materials and methods for details).
and thymines (18). Interestingly, mismatch repair-deficient
cells have been shown to tolerate the presence of high levels
of O6-methylguanine in their DNA (36) and it has been
suggested that this tolerant phenotype is due to the inability
of these cells to address O6-methylG/T and O6-methylG/C
mispairs in DNA. In mismatch repair-proficient cells, the
mismatch repair system could mediate the cytotoxic effects of
methylating agents by attempting to correct O6-methylG/T and
O6-methylG/C mispairs, whereby the failure of the polymerase
to find the perfect partner for the modified guanine would
eventually result in the formation of a cytotoxic double-strand
break (18). Like most mismatch repair-deficient lines, HCT15
cells are tolerant to alkylating agents (22). We therefore
decided to test whether the hMSH6 expressing clone H-5 has
become sensitized to alkylation treatment due to the restoration
of mismatch repair. As shown in Figure 4a, H-5 cells were
not significantly more sensitive to MNU treatment than the
control H-c clone. The HCT15/DLD1 cells had been shown
to express high levels of MGMT (22). In order to eliminate
possible effects of the methyltransferase, we repeated the
experiments in the presence of O6-benzylguanine, a competitive
inhibitor of MGMT (Figure 4b). Also under these experimental
conditions, no major differences in the sensitivity of the H-c
and H-5 clones to the methylating agent were observed.
hMSH6 expression restores the G2 checkpoint in H-5 cells
In the tumour cell line HCT11613, where the mismatch repair
defect was corrected by transfer of chromosome 3, MNNG
treatment led to a cell cycle delay in the G2 phase in both
asynchronous and synchronized cell populations, while the
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Fig. 5. Effect of MNNG treatment on the cell cycle progression of H-c and H-5 cells. The scattergrams show the cell cycle distribution of either untreated
H-c (a) and H-5 (c) or MNNG-treated H-c (b) and H-5 (d) cells 15 h after release from an HU block.
parental line HCT116 was almost unaffected by the treatment
(25). We decided to test whether the expression of hMSH6 in
HCT15 cells had a similar effect. The cells were synchronized
with HU, which blocks cells in early S phase. Following
release of the HU block, the percentages of cells in the different
stages of the cell cycle at various time points were studied by
FACS analysis. As shown in Table IV, in the case of the
control cell line H-c, most of the cells were in the S phase
2 h after HU block release. Between 7 and 12 h, most of the
cells traversed S phase and entered the G2/M phase, with the
following G1 phase appearing at 15 h post-release and a second
peak of S phase cells at 19 h. A similar progression was
observed with H-5 cells. However, following MNNG treatment,
differences between the two lines emerged. Thus, the control
H-c cell line displayed only a short delay in late S and G2,
with 30% of cells in S phase at 12 h and 20% in G2/M at
15 h. A much longer delay in late S phase was observed in
the treated H-5 cells, as demonstrated by the high percentages
of S phase cells at 9 and 12 h. Although these cells slowly
progressed to G2/M, at 15 and 19 h post-release, .30% of the
treated H-5 cells were still delayed in this phase.
Figure 5 shows the scattergrams at 15 h post-release, in
which the different progression through G2/M of H-c and
H-5 cells is shown. At this time point, most of the MNNG-
treated H-5 cells were delayed in late S phase and in G2/M
(Figure 5d), whereas a peak of G1 cells is already evident in
the treated control H-c cell line (Figure 5b).
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Discussion
The human colon cancer line HCT15 contains truncating
mutations in both alleles of the hMSH6 gene (19). These
mutations confer upon it a strong mutator phenotype, which
demonstrates itself in the form of significantly elevated muta-
tion rates (21) and instability of microsatellite sequences
consisting of mononucleotide repeats (19). The line is also
tolerant to methylating agents (22), its extracts lack mismatch
binding activity (10) and are defective in mismatch correction
(9). We have transfected these cells with a cDNA construct
expressing wild-type hMSH6 and have studied the effects of
expression of this mismatch repair protein on the phenotype
of the resulting stable transfectants.
The first surprising finding was that the transfection effici-
ency with the control, insert-less vector was significantly
higher than when the hMSH6-containing vector was employed.
Thus, while the latter experiments yielded only two hMSH6-
expressing clones, .200 were obtained in the control experi-
ment. This seems to indicate that hMSH6-expressing clones
were selected against.
Analysis of the H-5 clone revealed that although the hMSH6
protein could be detected in immunoblots (Figure 2a), it was
present in amounts substantially lower than the endogenous
hMSH2, its cognate partner in hMutSα. One reason for this
low level of expression is that the pCDNA expression vector,
integrated into the genome in three copies on average (data
not shown), produced only ~50% as much hMSH6 mRNA as
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was detected in the control HeLa cells (Figure 1b, compare
the specific signal with the intensity of the β-actin internal
control). However, this should not be critical in itself, as
immortalized lymphocytes from HNPCC patients with one
mutated mismatch repair allele have been reported to be
generally proficient in mismatch repair (37). The second
explanation could be that the hMSH6 protein, even though
expressed relatively efficiently, is subject to proteolytic
degradation or misfolding prior to associating with hMSH2.
Indeed, hMSH6 is known to be proteolytically labile. In
extracts of cells mutated in hMSH2 (e.g. LoVo and HEC59),
hMSH6 is present at barely detectable levels (10), suggesting
that it is degraded in the absence of its partner hMSH2. Our
previous studies showed that expression of hMSH6 without
hMSH2 in a baculovirus system also resulted in a significant
degradation of the former protein (13). Moreover, mixing of
hMSH2 and hMSH6 expressed separately gave only low
amounts of active hMutSα, while co-expression of the two
proteins yielded the biologically active mismatch binding
factor in high amounts (29), which suggests that the two
polypeptides probably interact during folding. In their natural
environment, the two genes are co-localized on chromosome
2p16 and it is likely that their expression is co-regulated,
thus ensuring effective heterodimerization. This hypothesis is
supported by the reports that transfer of chromosome 2 into
HCT15 cells (33) resulted in a substantial correction of the
mutator phenotype. The third possibility concerns the fact that
hMSH6 competes for hMSH2 with another MutS homologue,
hMSH3. Under normal circumstances, hMSH3 appears to be
expressed at low levels and therefore the relative ratio of the
hMutSα and hMutSβ heterodimers favours the former species
by a substantial margin (16). However, due to the absence of
hMSH6 in HCT15 cells, hMSH3 should be able to interact
with hMSH2 more successfully. Indeed, hMutSβ levels in
these cells have been reported to be elevated ~3-fold (16).
Although expression of hMSH6 would be expected to decrease
hMutSβ levels, this apparently failed to happen: the relative
quantities of hMSH2 and hMSH3 in extracts of H-5 cells were
similar to those detected in the control H-c line, at least as
judged by immunoblotting (data not shown). We must therefore
consider the possibility that expression of hMSH6 mRNA from
the pCDNA vector did not fully satisfy the criteria necessary
for successful translation of the protein and for its successive
heterodimerization with hMSH2.
Although present at low levels, the amount of active hMutSα
in the extracts of H-5 cells was nonetheless sufficient to
substantially restore mismatch binding activity (Figure 2b) and
mismatch repair (Figure 3a). Most importantly, expression of
wild-type hMSH6 in these cells greatly alleviated microsatellite
instability at the poly(A) marker BAT26 (Table I). It was
therefore somewhat surprising to discover that mutation rates,
measured at the HPRT locus, were reduced only 3-fold
(Table II) and that sensitivity of the hMSH6-expressing clone
H-5 to MNU was not significantly different from the H-c
control (Figure 4). How could this apparent discrepancy be
explained? In our opinion, the underlying reason for these
inconsistencies is the low level of hMutSα expression, coupled
with the substrate specificity of this heterodimeric mismatch
recognition factor. In vitro binding studies, carried out with
purified native (38) and recombinant (13) hMutSα demon-
strated that the preferred substrate is an IDL of one extrahelical
nucleotide, followed by the G/T mispair. Flanking sequences
also appear to play an important role in the efficiency of
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substrate recognition, whereby IDLs appear to be most effici-
ently recognized in the context of repeated motifs (39). As the
dissociation constant of hMutSα with respect to the G/T
oligonucleotide substrate is in the low nanomolar range (29,40),
we were able to detect mismatch binding activity in the extracts
of H-5 cells despite low protein amounts (Figure 2b). A
similar argument applies for the in vitro mismatch correction
experiments, which were carried out with substrates efficiently
recognized by hMutSα (Figure 4). Even lower concentrations
of hMutSα are required for efficient recognition of single
nucleotide IDLs, which are the underlying cause of microsatel-
lite instability in hMSH6-deficient cells. Correspondingly, the
poly(A) tract of the BAT26 marker was stabilized in H-5 cells.
In contrast to microsatellites, spontaneous mutations arising
in a gene such as HPRT are highly heterogeneous, including
all types of base/base mispairs and frameshifts. Some of these
will be good substrates for hMutSα and these might be
expected to be corrected even in the presence of low levels of
the factor. Other mispairs and, possibly, also frameshifts outside
microsatellites might not be bound by hMutSα sufficiently
well in order to initiate the mismatch correction process. As
shown in Table III, transition mutations, which result from
G/T or A/C mispairs, were down by 50% in H-5 cells, while
transversions, due to either G/A, or C/T mismatches, both
known to be poorly corrected in vivo (35), were elevated.
Restoration of sensitivity to methylating agents such as
MNU or MNNG would also be expected to be affected by
hMutSα concentration. The cytotoxic effects of methylating
agents are probably mediated by two distinct pathways.
One of these is most likely linked to abortive attempts of
the mismatch repair system to correct O6-methylG/T and
O6-methylG/C mispairs arising during replication of methyl-
ated DNA (18), whereby two concurrent mismatch repair
events in close proximity may cause a double-strand break.
Recent in vitro studies demonstrated that these mispairs are
indeed recognized by hMutSα (41). However, as its affinity
for O6-methylG/T and O6-methylG/C is substantially lower
than for the G/T mispair, the majority of these methylated
lesions would most likely remain unrecognized unless the cells
expressed high concentrations of the mismatch binding factor.
As this is clearly not the case for the H-5 line described here,
its sensitivity to alkylating agents is similar to the control
H-c line. The second response to DNA alkylation, or indeed
to DNA damage in general, is the deployment of a cell cycle
checkpoint, which allows the cell to repair the damage before
proceeding with DNA replication and/or mitosis. Such a delay
in cell cycle progression was documented in the mismatch
repair-deficient cell line HCT116, which failed to arrest follow-
ing treatment with methylating agents (25), but in which this
G2 delay was restored when the repair defect was corrected
by the transfer of chromosome 3, which carries a wild-type
copy of the hMLH1 gene. The ability of mismatch repair
proteins to signal to the apoptotic machinery was further
documented for the closely related cell lines MT1 and TK6
(42). Treatment of the latter, mismatch repair-proficient cells
with alkylating agents resulted in the elevation of p53 and p21
levels. No similar increase was observed in MT1 cells, which
are mutated in hMSH6. As treatment of both lines with
etoposide, an inhibitor of topoisomerase II, activated p53 and
p21 in both lines, we concluded that p53 was wild-type in
MT1 cells and that their failure to activate a p53 response
following alkylation treatment was due to the absence of
hMutSα-mediated damage detection. If we accept that mis-
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match repair proteins are involved in DNA damage signalling
to the apoptotic machinery or to the cell cycle checkpoint
control, this effect could be mediated by only a few molecules,
which might stall the replication fork by remaining bound at
O6-methylG/T or O6-methylG/C mispairs and thus bring about
a cell cycle arrest or delay. This hypothesis is supported by
the data presented in Table IV and Figure 5, where the stably
transfected H-5 line can be seen to be delayed in the late
S/G2 stage of the cell cycle following MNNG treatment, while
the control H-c clone progressed with only a short delay.
Mismatch repair deficiency was linked with a multitude of
phenotypic traits, ranging from microsatellite instability to
tolerance to alkylating agents. Earlier studies demonstrated
that transfer of chromosome 3 into hMLH1-deficient line
HCT116 (43) or of chromosome 2 into HCT15 and DLD1
cells (33), both lacking hMSH6, could bring about an almost
total reversion of the mutator phenotype. However, the caveat
of these studies was that whole chromosomes carry many genes
and thus that the correction effect could not be unambiguously
assigned to a single gene. Recently, Risinger et al. (44)
succeeded in overexpressing hPMS2 cDNA in HEC-1-A cells
and succeeded in restoring the repair of IDLs but not of base/
base mismatches. This partial phenotypic correction could be
explained by the discovery that these cells also harbour, in
addition to the mutated hPMS2, a mutated hMSH6 gene. We
now show that expression of hMSH6 in the HCT15 cell line
also resulted in only a partial reversion of its numerous
phenotypic traits. Unlike in the case of HEC-1-A cells,
however, this incomplete correction was most likely not caused
by the presence of a mutation in a second mismatch repair
gene. Rather, due to the low level of expression of the
transgenic protein, the observed effects were only small in
some instances. However, the reversion trend unambiguously
confirmed the association of the hMSH6 mismatch repair gene
malfunction with mononucleotide repeat instability, elevated
mutation rate and the G2 cell cycle checkpoint.
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